developer of the world’s only wireless cardiac pacing system for heart failure Market cap $350m As at 31 March US$7.7m cash + US$56.4m in short-term investments. Cash runway 18 months
EBR on track to submit the final module of its Pre-Market Approval (“PMA”) Application to the U.S. Food and Drug Administration (“FDA”) in Q3 2024. The Company is targeting FDA approval in Q1 2025. Stock is quite extremely illiquid 12 July CEO released a comprehensive update. Seen the SP tick up Initial TAM identified US$3.6b Unique product and solution/unmet need
